

BIO2015
International Convention



JAPAN Pavilion

• • • • •
Exhibitors' Directory

Booth 3649

June 16-18, 2015
Pennsylvania Convention Center
Philadelphia, USA

BIO 2015 / JAPAN Pavilion

It is a great honor for the Japan External Trade Organization (JETRO) to return to the annual BIO International Convention in 2015, our 13th participation in this leading international event since 2003. This year's JAPAN Pavilion features 20 exhibitors, many of them pioneers in such fields as biopharmaceuticals, diagnostics and regenerative medicine. Firms will be presenting their leading-edge technologies, products and services on this key global stage, and look forward to active business talks with prospective partners.

The JAPAN Pavilion features a business corner where visitors can take part in one-on-one meetings with exhibitors and utilize other business support and services. Panels introducing Japan's biotech industry are also on display in the pavilion.

JETRO Overview

The Japan External Trade Organization (JETRO) is the economic development agency of the Japanese government. JETRO promotes mutual trade and investment between Japan and the rest of the world. Utilizing our network of more than 70 overseas offices and 40 in Japan, JETRO carries out a range of activities, including: facilitating foreign direct investment into Japan; helping Japan's small and medium-size firms maximize their export potential; and promoting Japanese products abroad.

In the life science sector, JETRO provides market information and consulting to Japanese companies interested in entering foreign markets and to foreign companies interested in expanding into Japan. JETRO also coordinates periodic business matching opportunities at conferences and tradeshows around the world.

Table of Contents

Health Biotechnology

- ▶ **Bio-pharma** —————
 - BioComo Inc. 03
 - Oncolys Biopharma Inc. 04
 - Pola Pharma Inc. 05
 - ReqMed Company, Ltd. 06
 - ID Pharma Co., Ltd. 07
 - Momotaro-Gene Inc. 08
 - BioMedCore, Inc. 09
- ▶ **Medical Devices & Diagnostics** —————
 - Riken Genesis Co., Ltd. 10

Industrial Biotechnology

- ▶ **Industrial Biotechnology** —————
 - MicroBiopharm Japan Co., Ltd. 11

Biotechnology unclassified & Biotech-related Business

- ▶ **Biotechnology R&D Services** —————
 - Human Metabolome Technologies, Inc. 12
 - Pharma Foods International Co., Ltd. 13
 - Molcure,inc. 14
 - SCIVAX Life Sciences, Inc. 15
- ▶ **Devices, Equipment & Reagents** —————
 - Nomadic Bioscience Co., Ltd. 16
 - Tokyo Future Style, Inc. 17
 - CellFree Sciences Co., Ltd. 18
- ▶ **Bioinformatics** —————
 - World Fusion Co., Ltd. 19

Other Products & Services

- ▶ **Technology Transfer & TLO** —————
 - Kanazawa University Technology Licensing Organization (KUTLO) .. 20
 - MPO Inc. 21
 - iPS Academia Japan, Inc. 22

- > Japan's Life Science Market 23-24
- > Japan's Major Bio Clusters, Science Parks .. 25 and Incubators
- > Location of JAPAN Pavilion 26

BioComo

BioComo Inc.

Contact Person: Dr.Masayuki Fukumura
President & CEO

Address: Mie

E-mail: m-fukumura@biocomo.jp

TEL: +81-59-392-7333 FAX: +81-59-392-7333

URL: <http://www.biocomo.jp/>

Cutting edge technology for more effective and safer vaccines, BC-PIV

About Products/Service

> **Name:** BC-PIV with M2e influenza antigen, a universal influenza virus vaccine carrier,
BC-PIV: inactivated human Parainfluenza virus type 2 (hPIV2) vector generating smart incorporation way of a range of antigens and effective induction of humoral as well as cellular immune with safety profile.

Status: Preclinical

> **Name:** RSV F vaccine, RSV F prefusion site zero-targeted vaccine carriers. (1)vector encoding RSV F, (2)prefusion F protein formulated in BioComo's vector

Status: Research

> **Name:** BC-PIV/TAA, tumor-vaccine carrier effectively inducing CTL

Status: Research

> **Name:** BC-A 1-3, three novel adjuvant candidates effectively stimulating innate immune

Status: Research





Oncolys Biopharma Inc.

Contact Person: Mr.Yasunari Kashihara /
VP, Business Development

Address: Tokyo

E-mail: kashihara@oncolys.com

TEL: +81-3-5472-1578 **FAX:** +81-3-5472-1488

URL: <http://www.oncolys.com/en/>

Powering Future Oncotherapy

About Products/Service

- > **Name:** OBP-301 (Telomelysin®)
Status: Phase1/2
- > **Name:** OBP-801
Status: Phase1
- > **Name:** OBP-601
Status: Phase2
- > **Name:** OBP-1101 (TelomeScan F35)

Summary of products / Service / Technologies

OBP-301 (Telomelysin®) is Type 5 adenovirus in which the gene is modified to selectively replicate in cancer cells and kill them. Type 5 adenoviruses cause symptoms of the common cold, not severe pneumonia or death, and are present in the normal environment.

OBP-301 (Telomelysin®) shows potent anti-tumor activity selectively in cancer cells expressing telomerase, but not in normal cells. Thus, it is expected that OBP-301 (Telomelysin®) will show clinical safety. Because we expect OBP-301 (Telomelysin®) could be used loco-regionally, burden of this therapy may be limited. In combination with chemotherapy and/or radiotherapy, more potent anti-tumor activity would be expected. In addition, since the severe adverse events such as vomiting, hair loss, or hematopoietic failure has not been reported in Phase I clinical trial in the US, it is expected to improve QOL (Quality of Life) of patients. Phase I/II trial is ongoing with indication of HCC and clinical study for Esophageal cancer.

POLA PHARMA

Pola Pharma Inc.

Contact Person: Ms.Mayumi Shimma
Assistant Manager

Address: Tokyo

E-mail: m-fukumura@biocomo.jp

TEL: +81-3-5436-2461 **FAX:** +81-3-5436-5671

URL: <http://www.pola-pharma.co.jp/en/index.html>

***From cure to care,
our company's goal is to
provide dermatology solutions***

About Products/Service

> **Name:** TGF- β antagonist for scarring or fibrosis
(PR-4705, PR-4976)

Status: Preclinical

> **Name:** Hypoxic cell radiosensitizer for cancer
radiotherapy (Doranidazole: PR-350)

Status: Phase 3

Summary of products / Service / Technologies

Pola Pharma Inc. is a dermatology-focused drug-development based pharmaceutical company. One of our main products, Lulicon®, an anti-fungal topical agent, has been in the top share in anti-fungal topical agent market in Japan since 2012 and the development for its life cycle management is also successfully underway. In order to be a true "dermatology specialty pharma", we are enthusiastically looking for in-licensing opportunities from early to late development stages for the following dermatology indications: Acne, Atopic Dermatitis, Psoriasis, Pruritus and Pigmentation Disorder (other fields are also welcome).

We have 2 non-dermatology ranges of compounds, Doranidazole (hypoxic cell radiosensitizer for radiation therapy of cancer, Ph3) and PR-4705 & PR-4976 (TGF- β antagonist for scarring or fibrosis, preclinical) in our pipeline for out-licensing.



ReqMed Company, Ltd.

Contact Person: Mr.Kiyu Suzuki
Senior Manager

Address: Tokyo

E-mail: suzuki@reqmed.co.jp

TEL: +81-42-732-2207 **FAX:** +81-42-732-2208

URL: <http://www.reqmed.co.jp/>

Coordination of drug development, and arrangement of win-win partnerships.

About Products/Service

- > **Name:** Pentosan - Target Indication: Tropical Spastic Paraparesis (TSP)
Status: PIIa
- > **Name:** Pentosan - Target Indication: Mucopolysaccharidoses (MPS) and Osteoarthritis (OA)
Status: PIIa
- > **Name:** Eltoprazine - Target Indication: Dyskinesia in Parkinson's Disease
Status: PIIb
- > **Name:** Eltoprazine - Target Indication: ADHD and Cognitive Impairment Associated with Schizophrenia (CIAS)
Status: PIIa
- > **Name:** Consulting services to support partnering and collaboration

Summary of products / Service / Technologies

- i) Pentosan: PIIa study for TSP will be completed in 1H2015. PI study for MPS VI will be started in 2H2015. OA is expected as an indication with huge market.
- ii) Eltoprazine: PIIb study for Dyskinesia has been initiated in 1H 2015. Other studies for ADHD and CIAS are planned.
- iii) Consulting: In addition to the above, we can provide a variety of business opportunities, including late stage therapeutic programs and unique biotechnologies.



ID Pharma Co., Ltd.

Contact Person: Dr.Makoto INOUE
Director

Address: Ibaraki

E-mail: inoue@dnavec-corp.com

TEL: +81-29-877-5155 **FAX:** +81-29-877-5160

URL: <http://www.dnavec-corp.com>

***Innovative biopharmaceuticals
for regenerative medicine:
Safe, Efficient and Clinic- Ready!***

About Products/Service

- > **Name:** CytoTune®-iPS is a highly efficient and safe cell reprogramming kit. It generates integration free iPS cells from variety of cell types including blood cells.
Status: Research use kit is available on the market worldwide, GMP-grade kit will be released this summer.
- > **Name:** DVC1-0101 is a gene therapeutic medicine for the treatment of peripheral artery disease (PAD). It regains blood flow to ischemic limbs by enhancing vascularization (generation of new blood vessels).
Status: P2 clinical trial in progress in Japan; P1/2a planned in Australia.
- > **Name:** Vaccines for infectious diseases, including HIV
Status: P1 trial for HIV completed in England, Rwanda and Kenya; other vaccines in pre-clinical stage

Summary of products / Service / Technologies

We have successfully expanded the research-use market of CytoTune®-iPS globally (USA, EU, and Asia) through an internationally operating distributor. We are now looking at expanding the use to other business fields such as regenerative therapy (clinical use) and cell distribution service. In addition, we hope to discuss alliance/collaboration/co-development of gene medicine and gene vaccines with companies as possible partners. DVC1-0101 will be one topic for such discussion.



Momotaro-Gene Inc.

Contact Person: Mr.Hitoshi Shiomi
Chief Executive Officer

Address: Okayama Prefecture

E-mail: shiomi@mt-gene.com

TEL: +81-86-238-7848 FAX: +81-86-238-7848

URL: http://www.mt-gene.com/index_e.html

The Proof of Concept (POC) for a promising gene therapy for prostate cancer was established with First in Man (FIM) trials conducted in Japan. Phase I/IIa trials in the USA are ongoing with 10 times higher efficacy product.

About Products/Service

- > **Name:** Name: Adenovirus vector REIC/Dkk-3 cancer gene therapy
Status: Status: Phase I/IIa for prostate cancer in the US. IND submission for Malignant Mesothelioma in Japan.

Summary of products / Service / Technologies

We are seeking pharmaceutical partners for our adenovirus vector REIC (Ad-REIC) gene therapy with cancer specific apoptosis and enhanced immunity to prostate cancer and malignant mesothelioma.





BioMedCore, Inc.

Contact Person: Mr..Koichi Kuromi
Director, Business Development

Address: Kanagawa

E-mail: kuromik@bmc core.co.jp

TEL: +81-45-501-1714 **FAX:** +81-45-501-1715

URL: <http://www.libmec.com>

***Providing dedicated liposome
manufacturing equipment and service.***

About Products/Service

- > **Name:** Retinal DDS drug formulation with liposome expected to alternate from injection to eye drop administration: Liposomal drug formulation technology and the licensable patent in global.
Status: Pre-clinical
- > **Name:** Contract/joint development of liposomes for drug formulation and sample drug preparation using our proprietary LibMec method, which allows us to manufacture high quality commercial-scale aseptic liposomes.
Status: CDMO
- > **Name:** BN-1000: Stand-alone, compact size, automated control equipment for liposomal drug (i.e.. chemotherapy drug, vaccine, RNA carrier) development adopted single use GMP components in a clean isolation chamber.
Status: Custom designed equipment
- > **Name:** MCL (Mannose Coated Liposome) as a Th1 strong adjuvant for vaccine, DDS carrier or in vitro CTL assay tool.
Status: Seeking a co-development partner

Summary of products / Service / Technologies

BioMedCore has patented technology for liposomal DDS drug formulation and production, especially for ophthalmic DDS, RNA delivery and vaccine development applications. We can serve as your contract manufacturer of liposomes as well as conduct joint development using our liposome-related patented technologies. Our BN-1000 provides a dedicated system for liposomal drug development. It will enable faster, more efficient drug development with greater ease and less cost. We are eagerly looking for opportunities for collaboration, technology transfer and equipment sales.



Riken Genesis Co., Ltd.

Contact Person: Ms.Saeko Nagatomi
Manager, Sales & Marketing Development Department

Address: Tokyo

E-mail: saeko.nagatomi@rikengenesis.jp

TEL: +81 3 3839 8045 **FAX:** +81 3 3839 8046

URL: <http://www.rikengenesis.jp/en/index.html>

The realization of personalized medicine utilizing gene analysis technology

About Products/Service

- > **Name:** Onco Guide KRAS - Target genes - KRAS codon12&13
Status: CE IVD
- > **Name:** F-PHFA: New Standard in Somatic Mutation Detection Target genes - KRAS, BRAF, NRAS, EGFR, PI3K
Status: RUO
- > **Name:** BLV (bovine leukemia virus) Detection kit
Status: RUO

Summary of products / Service / Technologies

Riken Genesis provides genetic analysis products based on its proprietary F-PHFA assay platform. F-PHFA is a sensitive, robust, and easy-to-use assay which suits best for somatic mutation analysis for cancer research. F-PHFA products include analysis kit for KRAS, BRAF, NRAS, EGFR, PI3K, and ABL genes. Customized kits for research projects are also available.

Riken Genesis is fully capable of regulatory affairs to develop IVD kit in the world . We welcome the partnership with pharmaceutical companies to develop companion diagnostics.



MicroBiopharm Japan Co., Ltd.

MicroBiopharm Japan Co., Ltd.

Contact Person: Ms.Asako Toyoda
R&D Division, Strategic Planning Team Leader

Address: Tokyo

E-mail: R_D-Info@microbiopharm.com

TEL: +81-3-6265-1761 **FAX:** +81-3-6265-1768

URL: <http://www.microbiopharm.com/en/index.html>

Fermentation support & service for your product discovery and development

About Products/Service

- > **Name:** Fermentation contract manufacturing service
Status: Non-mammalian cells, GMP, GILSP compliant
- > **Name:** Strain/Enzyme improvement
Status: Improving manufacturing strain matching your request
- > **Name:** Process improvement
Status: Seamless transfer of fermentation and purification process from laboratory to industrial scale
- > **Name:** Provision of Extracts managed with our original database, which includes ingredient information
- > **Name:** Bioconversion services using the world's most efficient cytochrome P450 (Hydroxylation enzyme) library
Status: 158 types of P450

Summary of products / Service / Technologies

MicroBiopharm Japan (MBJ) has over 50 years' industrial fermentation experience in manufacturing of APIs, intermediates, agricultural antibiotics utilizing improved processes of fermentation and biotransformation. We have significant experience with strain/enzyme improvement for manufacturing. In addition, we provide drug discovery support services by offering unique natural source libraries (microorganisms, extracts, compounds) and the P450 (hydroxylation enzyme) library.



Human Metabolome Technologies, Inc.

Contact Person: Dr.Takushi Oga
Business Development Manager

Address: Yamagata

E-mail: takushi.oga@humanmetabolome.com

TEL: +81-23-5251447 FAX: +81-23-5251450

URL: <http://humanmetabolome.com/en>

Next Generation Metabolomics

About Products/Service

- > Name: Metabolic profiling
Status: P1
- > Name: CARCINOSCOPE™
Status: Preclinical

Summary of products / Service / Technologies

Metabolomics, quantitative analysis of small molecules, is a powerful tool for biomarker discovery. HMT provides metabolomic profiling using unique CE-MS technology which is the best platform for accurate quantization of essential hydrophilic metabolic intermediates. Together with HPLC-MS based lipid profiling, we delivers on comprehensive metabolomic discoveries. HMT also uniquely provides targeted quantitative profiling focusing on over 100 key intermediates in focused cancer metabolism.





Pharma Foods International Co., Ltd.

Contact Person: Mr.Masayoshi Toyoura
General Manager Biomedical R&D Dept.

Address: Kyoto

E-mail: toyoura@pharmafoods.co.jp

TEL: +81-75-394-8600 **FAX:** +81-75-394-0099

URL: <http://www.pharmafoods.co.jp/english/index.html>

Innovative antibody generation technology

About Products/Service

- > **Name:** Avian Lead Antibody GENE (ALAGENE)
technology service
Status: Currently available
- > **Name:** New antibody drug against Rheumatoid arthritis
Status: Establishment of humanized antibody
- > **Name:** New antibody drug for cancer therapy
"Next generation of immuno checkpoint inhibitors"
Status: Establishment of humanized antibody

Summary of products / Service / Technologies

The chicken is a useful animal for generating specific antibodies against conserved mammalian proteins because of the phylogenetic differences between chickens and mammals.

Avian Lead Antibody GENE (ALAGENE) technology allows for: 1) Production of membrane protein using chicken cell; 2) Establishment of specific antibodies using phage display technique; 3) humanization of chicken monoclonal antibodies.

We are excited to introduce this technology service and our pipeline at BIO 2015.



Molcure,inc.

Contact Person: Mr.Yoichiro Hara
COO

Address: Tokyo

E-mail: hara@molcure.com

TEL: +81-50-5867-6542

URL: <http://molcure.com>

***Rapid design of leading
antibody candidates with
high quality and high diversity***

About Products/Service

> Name: Abtracer

Status: Antibody screening / engineering service

Summary of products / Service / Technologies

Our Abtracer system is a patent-pending framework combining the phage display technique and NGS-analysis of antibody DNA sequences using machine learning algorithm. We provide a groundbreaking new service that enables pharmaceutical companies who are developing new antibody drugs to identify antibody candidates 6x faster and with 10x greater probability of identifying the lead antibody for the next blockbuster drug. By using Abtracer, our clients can maximize the potential of their current antibody libraries and screening methods.



**SCIVAX Life
Sciences, Inc.**

Contact Person: Mr. Atsushi Mizuno
Director

Address: Kanagawa

E-mail: atsushi_mizuno@scivaxls.com

TEL: +81-44-580-3008 **FAX:** +81-44-580-3006

URL: <http://www.scivaxls.com/en>

NanoCulture Plate (NCP) for 3D Cell Culture

About Products/Service

- > **Name:** Contract research service for anti-cancer drug screening using by 3D cancer model
- Screening of new anti-cancer candidate
 - Screening of EMT inhibitor
 - Drug sensitivity assay

Status: On the market

- > **Name:** Contract research service for Hepatocyte toxicity assay using by 3D liver model

Status: In development

- > **Name:** Target gene or drug candidate for inhibiting EMT (Epithelial-Mesenchymal Transition)

Status: Lead compound

Summary of products / Service / Technologies

SCIVAX Life Sciences is a leading 3D cell culture technology company. With our bio-mimetic, surface micro-processing technology, we culture multi-cellular spheroids on a film with ECM mimicking structure, which can simulate in-vivo like micro-environment. With our unique 3D cell culture technology, we provide various contract research services, such as follows:

- Anti-cancer drug screening
- Hepatocyte toxicity assay

In addition, we developed an original 3D culture screening method for EMT inhibitor. The EMT inhibitory candidates were discovered as an index of the spheroid morphology change using by the screening method.

Nomadic
Bio Science**Nomadic Bioscience Co., Ltd.**

Contact Person: Dr.Satoshi Sato
CEO

Address: Okayama

E-mail: ssato@nomadicbio.com

TEL: +81(0)86-286-9507 FAX: 81(0)86-286-9507

URL: <http://www.nomadicbio.com/en>

***Improve Antibody Purification
Efficiency Without Using
Acid Treatments***

About Products/Service

- > **Name:** Temperature responsive Protein A resin for purifying/screening for therapeutic antibody
Status: Preclinical use

Summary of products / Service / Technologies

We bring innovation to antibody purification. Our Protein A resin (Byzen Pro®) reduces the manufacturing cost of antibody drugs and antibody-conjugated biologics by eliminating risk of antibody aggregation. The engineered Protein A elutes antibodies at a neutral pH without using acid by simply changing temperature, significantly increasing the recovery rate of antibodies. We are seeking clients that wish to test this breakthrough technology.





Tokyo Future Style, Inc.

Contact Person: Mr. Takashi Endo
President

Address: Ibaraki

E-mail: endo@tokyofuturestyle.com

TEL: +81-29-851-9222 FAX: +81-29-851-9220

URL: <http://www.tokyofuturestyle.com/english/>

Novel products based on Japanese Bio-Venture technologies for the global market

About Products/Service

- > **Name:** BAC kit for in-gel digestion of proteome analysis
Status: Available for the market
- > **Name:** Cyclic-di-GMP, cyclic-di-AMP and cyclic AMP-GMP; novel agents to inhibit biofilm formation by microorganisms
Status: Available for the market
- > **Name:** Nucleotide sugars - substrate of glycosyltransferase
Status: Available for the market
- > **Name:** EMARS reagent "Ar-Flu" : This research reagent was developed as a novel approach for cell membrane study
Status: Available for the market
- > **Name:** DNA extraction kit for environmental samples
Status: Available for the market

Summary of products / Service / Technologies

Tokyo Future Style, Inc. is marketing Japanese novel products from universities and bio venture companies to the global market. Functional nucleic acids (cyclic-di-GMP, cyclic-di-AMP and cyclic di-AMP-GMP) are expected to be a new treatment of biofilm. The BAC kit is an attractive kit to effectively prepare a sample for proteome analysis. EMARS reagent was developed to identify molecules interaction on cell membrane.



CellFree Sciences Co., Ltd.

Contact Person: Mr.Keiki Yokomoto
Executive Officer, Head of Sales & Marketing Division

Address: Kanagawa

E-mail: k-yokomoto@cfsciences.com

TEL: +81-45-500-2119 **FAX:** 81-45-500-2117

URL: <http://www.cfsciences.com/eg/index.html>

Accelerating Protein Research with Wheat-Germ Cell-Free Protein Expression System

About Products/Service

- > **Name:** High-Quality Wheat Germ Extracts "WEPRO"
for cell-free protein synthesis
Status: Existing product
- > **Name:** "Proteoliposome Expression Kit" is a new kit for
membrane protein expression using our Wheat-
Germ Cell Free Protein Expression System.
Status: Existing product
- > **Name:** Automatic Protein Synthesizer "Protomist DTII",
"Protomist XE"
Status: Existing product
- > **Name:** Custom Protein Synthesis Service
Status: Existing service

Summary of products / Service / Technologies

ENDEXT technology, originally invented by Prof. Yaeta Endo (Ehime University/UCSC) and commercialized by CellFree Sciences, is a wheat germ cell-free protein production platform. Proteins from a wide range of organisms, including humans, can be obtained without codon optimization at high success rates ready for functional and structural analysis. ENDEXT technology has been instrumental in the success many R&D projects, with numerous examples published in leading scientific journals.



World Fusion Co., Ltd

Contact Person: Mr.Kozo Kawahara
President

Address: Tokyo

E-mail: kkawahara@w-fusion.co.jp

TEL: +81-3-3662-0521 FAX: +81-3-3662-0522

URL: <http://www.w-fusion.com/>

***Enormous knowledge enables
accelerated drug discovery
and diagnostic tool development***

About Products/Service

> Name: Life Science Knowledge Bank (LSKB)

Status: Available now

> Name: Metagenome@KIN

Status: Available now

Summary of products / Service / Technologies

The LSKB is a knowledge station which utilizes data mining techniques to explore the optimum compound and the target protein/gene.

More than 60M non-redundant compounds have been cataloged in LSKB, and the variety of the interactions of compounds with proteins, genes, diseases, and tissues are included. We are developing a variety of analysis tools using LSKB knowledge and informatics technologies.

Metagenome@Kin is one of the examples.

We are developing diagnostic/ analytical tools for pharmaceuticals, food and cosmetics companies. In addition, we also provide data analysis services.

KUTLO

Kanazawa University Technology Licensing Organization (KUTLO)

Contact Person: Dr.Kuninori Kinoshita
Executive Vice President

Address: Ishikawa

E-mail: kinoshita@kutlo.co.jp

TEL: +81-76-264-6115 **FAX:** +81-76-234-4018

URL: <http://kutlo.co.jp/>

Cell-Sheet Engineering to Induce Osteogenic Potential of Adipose Derived Stem Cells and Artificial Bone Formation

About Products/Service

- > **Name:** Adipose Derived Stem Cells (ADSCs) sheets to present high osteogenic potential and mechanical strength
Status: Preclinical

 - > **Name:** Artificial bone from ADSCs sheets
Status: Preclinical
-

Summary of products / Service / Technologies

This technique does not require expensive devices and could be applied to human ADSCs, canine ADSCs, rabbit ADSCs, etc. ADSCs sheets can be fabricated in 7-10 days, and provide high osteogenic capacity and mechanical strength. Applications include:

- Wrap for artificial or grafted bones
- Transplantation for reconstruction of bone nonunion or defects
- Transplantation into the bone necrosis for bone reconstruction





MPO Inc.

Contact Person: Mr.Masanori Inoue
Technology Licensing Division

Address: Kanagawa

E-mail: minoue@mpo-inc.co.jp

TEL: +8-44-979-1631 FAX: +81-44-979-1632

URL: <http://www.mpo-inc.co.jp>

MPO represents advanced technologies and services from some of Japan's leading medical schools and universities

About Products/Service

- > **Name:** Anti-inflammatory agent as effective as glucocorticoids without side effects
Status: Preclinical
- > **Name:** A genetic diagnosis tool for virus-related diseases with next generation sequencer
Status: Preclinical
- > **Name:** Surgical devices
Status: Preclinical
- > **Name:** Regenerative medicine using differentiated melanocytes from iPS cells
Status: Preclinical
- > **Name:** Platelet-rich plasma (PRP) therapy
Status: Start-up company; Clinical study

Summary of products / Service / Technologies

We support a wide range of life science technology transfers in Japan. We are looking for development partners, distributors and manufacturers for the following products:

1. The NF- κ B inhibitory anti-inflammatory drug
2. Sequence analysis of the viral integration sites on the human genome
3. Innovative microwave scissors for seamless surgery
4. Highly-efficient differentiation methods of melanocytes from iPS cells
5. Concentrated PRP separation methods, which have been used in clinical studies



iPS Academia Japan, Inc.

Contact Person: Dr. Shigeki Miyawaki
Senior Manager, License Division

Address: Kyoto

E-mail: miyawakicell4@ips-ac.co.jp

TEL: +81-75-754-0625 **FAX:** +81-75-761-3577

URL: <http://ips-cell.net>

iPS cells : Applications for human welfare!

About Products/Service

> **Name:** Patents and applications on induced pluripotent stem cells (iPS cells) technologies and relations (patent portfolio consisting of reprogramming, differentiation and other technologies related to iPS cells)

Status: Issued or Pending

Summary of products / Service / Technologies

iPS Academia Japan has been granted the right to sublicense iPS cell-related patents from Kyoto University and others. The patents in our portfolio include the reprogramming patent for four factors: Oct3/4, Klf4, c-Myc and Sox2, which was invented by 2012 Nobel Laureate Prof. Yamanaka of the Center for iPS Cell Research and Application (CiRA) at Kyoto University.

For-profit entities, we grant non-exclusive licenses with appropriate and reasonable royalty fees depending on the scope of the license.

* Patents issued in USA : US8048999, US8278104, US8058065, US8129187 and others. For more information, visit <http://ips-cell.net>.

Japan's Life Science Market


The biotechnology industry occupies an important position in 21st century Japan. Japan is the second-largest life science market in the world after the United States, occupying about 10% of the market in each of the global drug and medical device markets. According to Datamonitor, the Japanese biotechnology market had total revenues of \$43.3 Billion USD in 2012. By 2017, the market is expected to grow to \$53.8 Billion USD.

The trend of open innovation promotes the growth and activities of Japanese biotechnology companies (currently over 500) and the growth of their licensing out of contracts. The competitiveness of the Japanese biotechnology industry is largely underpinned by the country's high share of biotechnology patents filed under PCT and the high amount of biotechnology R&D expenditures in the business sector.

The Japanese government recognizes biotechnology as a key driver of future economic growth and strongly supports both domestic biotech initiatives and its global development. Japan's life science community is aggressively pursuing new treatments for oncology, pain management, cognitive & neurological disorders and is a world leader in regenerative medicine. In 2012, Dr. Shinya Yamanaka, Professor and Director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, was awarded the Nobel Prize for Physiology/Medicine for his research into iPS cell therapy. Japanese researchers are eager to connect & collaborate with innovative partners from around the world to help bring new life-saving treatments to market.

Global Drug Market Share by Country


2012 World Pharmaceutical Markets Fact Book



Sales of Biological Products (2008)


Sales in 2008 totaled 927 Billion Yen (approximately \$9.1 Billion USD), up from 850 Billion Yen in 2006. Sales are expected to continue to grow as new drugs are approved and Japan's population ages. (METI, 2009 Fundamental Research Report of Bio Industry Creation)

Breakdown of Sales of Bio-Products (Billion Yen) 2008



Breakdown of Pharmaceutical Production Amounts (100 Million Yen)

MHLW, Statistics of Production by Pharmaceutical Industry, 2012



Japan's Major Bio Clusters, Science Parks and Incubators

Hokkaido Bio Technology Industrial Cluster Forum (Sapporo)

Northern Advancement Center for Science & Technology (NOASTEC) (Sapporo)

Tohoku Techno Arch (Sendai)

Tsuruoka Metabolome Cluster (Tsuruoka)

Tsukuba Science City Network (Tsukuba)


Kazusa Akademia Park (Chiba)

Metropolitan Bio Network / Japan Bioindustry Association (Tokyo)

Yokohama Kanagawa Bio-Network (Yokohama)

Fuji Pharma Valley Project (Shizuoka)

Hokuriku Innovation Cluster for Health Science (Kanazawa)



Mie Medical Valley Project (Tsu)

Nagahama Bio Cluster/Nagahama Science Park (Nagahama)

Kyoto Biocity Concept/Advanced Scientific Technology & Management Research Institute of KYOTO (Kyoto)

Senri Life Science Foundation/Northern Osaka Bio Medical Cluster (Osaka)

Kobe Biomedical Innovation Cluster/Foundation for Biomedical Research and Innovation (Kobe)

Saito Life Science Park (Osaka)

Kansai Bio-Industry Development Organization (Osaka)

Hiroshima Bio Cluster (Hiroshima)

Shikoku Techno Bridge Forum (Takamatsu)

Fukuoka Bio Valley Project (Kurume)

Kyushu Bio Cluster/Kyushu Bio Cluster Conference (Kumamoto)

Okinawa Industry Promotion Public Corporation (Naha)

Location of JAPAN Pavilion



JETRO WILL HAVE A JAPAN BOOTH AT BIO-EUROPE 2015

21th ANNUAL INTERNATIONAL PARTNERING CONFERENCE

BIO-EUROPE 2015

NOVEMBER 2-4, 2015

MUNICH, GERMANY / International Congress Center Munich

>>For more information, please email:

sid@jetro.go.jp



This material is issued and distributed by JETRO Chicago, One East Wacker Drive, Suite 600, Chicago IL 60601, which is registered under the Foreign Agents Registration Act of 1938, as amended. This material is filed with the Department of Justice where the required registration statement is available for public inspection. Registration does not indicate approval of this material by the United States Government

* All information in this publication is verified to the best of JETRO's ability. However, JETRO does not accept responsibility for any loss or damage arising from any reliance on it.